Drug intelligence / Profile preview

decaffeinated green tea extract plus

Development stage: Preclinical
Administration: Oral

Overview

Decaffeinated green tea extract plus (dGTE+) is a dietary supplement combining decaffeinated green tea extract (standardized to 400 mg/d (-)-epigallocatechin-3-gallate or EGCG), quercetin (50 mg/d), and alpha-lipoic acid (150 mg/d). This combination has been investigated for its effects on fat oxidation, body composition, and cardio-metabolic health in overweight individuals engaged in regular exercise. Clinical studies have shown that dGTE+ can improve maximal fat oxidation and substrate utilization during exercise, and also lead to a reduction in LDL-c.

Other names: dGTE+

Targets

COMT (Catechol-O-methyltransferase)

Beyond the preview

Go deeper on decaffeinated green tea extract plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on decaffeinated green tea extract plus.

Explore the full profile